Unicycive - רווח למניה ב-12 החודשים האחרונים UNCY

The price action history of Unicycive Therapeutics (UNCY) on the GURU.Markets platform demonstrates the 43.90 indicator. The company's revenues are based on bringing therapies for renal pathologies to market, specifically phosphate-lowering drugs. Primary capital is generated through payments for life-saving treatment by insurance companies and hemodialysis centers. Meanwhile, the certified base and contract sites are currently focused on scaling production lines and releasing trial batches.
פילוחי מדדים פיננסיים ומדדי שוק עבור Unicycive Therapeutics, Inc (UNCY)

The scalability dynamics of Unicycive Therapeutics (UNCY) drugs are reflected in the EPS YoY volatility over the last 12 months on the GURU.Markets platform, linking operational success to profitability. This indicator measures the percentage shift in net earnings per share year-over-year, allowing investors to assess the speed of commercialization for unique formulas and confirm the sustainability of the business model through real growth in asset returns.